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Edited by Frances ShannonAbstract Smad ubiquitination regulatory factor 2 (Smurf2), a
ubiquitin ligase for Smads, plays critical roles in the regulation
of transforming growth factor-b (TGF-b)-Smad signaling via
ubiquitin-dependent degradation of Smad2 and Smad7. We
found that TGF-b stimulates Smurf2 expression. TGF-b acti-
vated the Smurf2 promoter in a TGF-b responsive cell lines,
whereas IL-1a, PDGF and epidermal growth factor did not.
TGF-b-mediated Smurf2 promoter activation was inhibited by
Smad7 or an activin receptor-like kinase 5 inhibitor but not by
dominant negative Smad or disruption of Smad-binding elements
in the promoter. Moreover, inhibition of the phosphatidil inositol
3 kinase (PI3K)/Akt pathway suppressed TGF-b-mediated
Smurf2 induction. These results suggest that TGF-b stimulates
Smurf2 expression by Smad-independent pathway such as
PI3K/Akt pathway via TGF-b receptor.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transforming growth factor-b (TGF-b) playsmultifunctional
roles in regulating the cell cycle, apoptosis, diﬀerentiation, and
extracellular matrix production [1]. TGF-b exerts these biologi-
cal functions through two distinct TGF-b receptors, type I
(TbRI) and II (TbRII) [1,2]. After TGF-b binding to TbRII,
TbRI is activated then the downstream receptor-regulated
Smads (R-Smads) are phosphorylated. The phosphorylated
R-Smads (Smad2 and 3) associate with a co-Smad, Smad4,
and enter the nucleus to modulate the transcription of TGF-b
responsive genes. Smad7, an inhibitory Smad (I-Smad) blocks
R-Smad phosphorylation by binding to the receptors, and pro-
motes ubiquitination and degradation of the receptor com-Abbreviations: R-Smad, receptor-regulated Smad; Smurf, Smad ubiq-
uitination regulatory factor; TGF-b, transforming growth factor-b;
ALK, activin receptor-like kinase; PI3 kinase, phosphatidil inositol 3
kinase
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studies have demonstrated that Smads are critical transducers
for TGF-b signaling, however, several papers have suggested
that Smad-independent pathways also exist [5]. TGF-b activates
extracellular kinase (ERK), p38 MAP kinase [6] and Jun N-ter-
minal kinase (JNK) [7]. Additionally, the phosphatidil inositol 3
kinase (PI3K)/Akt pathway is also activated by TGF-b [8].
TGF-b signaling is regulated by the ubiquitin–proteasome
pathway [9]. Ubiquitin-mediated proteolysis controls cellular
amounts of short-lived proteins such as cell cycle regulators
or signal transducers [10]. Polyubiquitinated proteins conju-
gated as a result of collaboration among a ubiquitin-activating
enzyme (E1), ubiquitin-conjugation enzyme (E2), and ubiquitin
ligase (E3) are selectively recognized and hydrolyzed by the 26S
proteasome [10]. The speciﬁcity of target protein selection is de-
ﬁned by ubiquitin ligases. Smad ubiquitination regulatory fac-
tors (Smurfs), a HECT type ubiquitin ligase, regulate cellular
amounts of TGF-b receptors and various Smads via the ubiqui-
tin–proteasome pathway [11]. It has been reported that Smurf1
promotes ubiquitin-dependent degradation of TbRI as well as
Smad1, Smad5 and Smad7 [12]. Smurf2 is thought to contribute
to ubiquitination of the TGF-b receptor complex as well as
Smad1, Smad2, Smad5, Smad7 and a transcriptional co-repres-
sor, SnoN, but not Smad3 [13]. Smurf2 ubiquitinates the Smad2
phosphorylated by TbRI during TGF-b signaling.
Several reports have indicated that Smurf2 plays important
roles in biological events such as development, tumor forma-
tion and disease progression [14,15], and TGF-b has been
shown to play a signiﬁcant role in the progression of kidney
ﬁbrosis [16]. We recently suggested that Smurf2 increases in
nephritic kidneys to promote ubiquitin-dependent degradation
of Smad2 and Smad7 [17,18]; however, the mechanism of
Smurf2 gene expression was unknown. In the present study,
we searched for the extracellular signaling molecule that regu-
lates Smurf2 expression, and found that TGF-b increased
Smurf2 mRNA and its protein level. Here, we discuss the
mechanisms involved in the transcriptional activation of the
Smurf2 gene.2. Materials and methods
2.1. Plasmids
Smurf2 reporter plasmidswere constructed as follows: twoDNAfrag-
ments of the 1067 to 262 region and 277 to +103 region of C57/
BL6Jmouse Smurf2 gene were prepared by PCR (transcription start siteblished by Elsevier B.V. All rights reserved.
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pBluescript II (Toyobo, Osaka, Japan) to generate pBlueSf-1 and pBl-
ueSf-2, respectively. The inserts were subjected to DNA sequencing
and conﬁrmed that it had no error. To generate a plasmid PGV-Bsf-
1067 (containing the 1067 to +103 region), KpnI–NheI fragment
(1067 to 273) from pBlueSf-1 and NheI–HindIII fragment (272 to
+103) from pBlueSf-2 were inserted into the KpnI–HindIII site of
PGV-B (Toyo Inki Co., Ltd., Japan), a reporter plasmid without pro-
moters and enhancers. To generate a plasmid PGV-Bsf-272 (containing
the272 to +103 region), NheI–HindIII fragment (272 to +103) from
pBlueSf-2was inserted intoNheI–HindIII site ofPGV-B.Dominantneg-
ative Smad3 (DN-Smad3) (Samd3D407E) and kinase-negative Akt
(Akt-KN) were provided by Dr. Miyazono (Tokyo University, Tokyo,
Japan) and Dr. Gotoh (Tokyo University, Tokyo, Japan), respectively.2.2. Site-directed mutagenesis
Site-directed mutagenesis for construction of reporter plasmids con-
taining mutant Smad binding element (SBE) (wild-type, AGAC, to
mutant-type, ACTG, or wild-type, GTCT, to mutant-type, CAGT)
were performed by PCR-mediated splicing after overlap extension
using a 5 0-primer containing XbaI site, a 3 0-primer containing HindIII
site and a mutant primer set (sense and antisense) containing mutant
SBE at 203, 130, 55, +28 or a mutant primer +80 (antisense).
The mutant primer +80 harbors HindIII site at the 5 0-end. The ampli-
ﬁed XbaI–HindIII fragment (272 to +103) containing mutant SBEs
were then subcloned into NheI–HindIII site of PGV-B. The subcloned
fragment was subjected to DNA sequencing to verify the clone. We ﬁ-
nally constructed a mutant reporter plasmid PGV-Bsf-272-mt-5SBE
with all ﬁve SBE mutations. The PCR-primer sequences are as
follows (mutant bases are in boldface and underlined): 5 0-primer:
5 0-CGATCTTTCAGTGATCTAGATGGTCAGTAGG-3 0, 3 0-primer:
5 0-ACCCAAGCTTGGGAGCGGACGGTGCG-3 0, mutant primer
203: 5 0-TTCGGGGCCCACAGTGGGCCGTGGC-30, mutant pri-
mer 130: 5 0-GGCGCAGGACTGCCTCGCCCAC-3 0, mutant pri-
mer 55: GCCCCGCCCCCCAGTCCTCCCCGCC, mutant primer
+28: 5 0-GTTCTCTCACTGAAGAGGGCGGGCGGAG-3 0, mutant
primer +80: 5 0-ACCCAAGCTTGGGAGCGGACGGTGCGAA-
CAGTGCTGAGGC-3 0.
2.3. Cell culture and reporter assay
HepG2 cells and HeLa cells were grown in DMEM containing 10%
FBS. PGV-Bsf-272 or PGV-Bsf-1067 were transfected with pCMV-b-
gal into HepG2 cells by the calcium phosphate method and into HeLa
cells with FuGENE6 Transfection Reagent (RocheMolecular Diagnos-
tics) [19]. After 24 h, the cells were washed three times with PBS then
incubated in 0.2%FBS–DMEMwith TGF-b at the indicated concentra-
tion. Forty-eight hours after transfection, cell lysates were prepared and
the activities of luciferase and b-galactosidase were measured as previ-
ously described [19]. All reporter assays were performed as triplicates
and luciferase values were normalized to b-galactosidase levels.Fig. 1. TGF-b-dependent increase of Smurf2 mRNA and protein. (A)
Induction of Smurf2 mRNA by TGF-b in a time-dependent manner.
Exponentially growing HepG2 cells were washed with PBS and treated
with 400 pM TGF-b for 0, 2, 4 or 6 h after the conditioned medium
was changed to 0.2% FBS–DMEM. Total RNA was extracted from
these cells and quantiﬁed by real-time RT-PCR. The Smurf2 mRNA
levels were normalized to GAPDH mRNA levels determined as an
internal control. N = 4 for each group. (Results are means ± S.D.) (B)
Induction of Smurf2 protein by TGF-b in a time-dependent manner.
HepG2 cells were cultured with 400 pM TGF-b for 0, 12 or 24 h in
0.2% FBS–DMEM. TGF-b was added to the cells every 6 h. These cell
lysates were subjected to Western blot analysis with rabbit anti-human
Smurf2 (Santa Cruz) and mouse monoclonal anti-a-tubulin (Sigma)
(upper panel). The protein levels of a-tubulin were determined as an
internal control. The densitometric ratios of the Smurf2 bands vs the a-
tubulin bands were calculated relative to the 0 h sample (lower graph).2.4. RNA isolation and quantitative analysis of mRNA by real-time
RT-PCR
HepG2 cells were treated with or without 400 pM TGF-b for 0, 2, 4,
or 6 h after the conditioned medium was changed to 0.2% FBS–
DMEM. Total RNA was extracted from the cells using ISOGEN
(Nippon Gene, Inc., Tokyo, Japan) [17,18]. Reverse transcription
(RT) was performed with 8.67 lg of total RNA using a cDNA cycle
kit (Invitrogen, Tokyo, Japan). After completion of the cDNA synthe-
sis, PCR with QuantiTect SYBR Green PCR Master Mix (Qiagen K.
K.) was carried out for analysis of Smurf2 mRNA using a LightCycler
(Roche Diagnostics, Tokyo, Japan). The PCR-primer sequences were
as follows: sense, 5 0-TAGCCCTGGCAGACCTCTT-3 0; antisense,
5 0-CTTGTTGCGTTGTCCTCTGT-30. The ratios of Smurf2 mRNA
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were
statistically evaluated by Scheﬀes t test using Statview (Abacus Con-
cept, Inc., Berkeley, CA).
2.5. Electrophoretic mobility shift assays (EMSA)
Nuclear extracts from HepG2 cells treated with or without 100 pM
TGF-b for 4 h were prepared as described previously [20]. In the EMSA
assay, a 32P-labeled double stranded DNA probe (10 fmol) was incu-
bated with 4 lg of nuclear extracts under previously described condi-tions [20]. For competition and supershift experiments, 50–200 fold
molar excess of annealed oligonucleotides, 5 lg of anti-Smad3 antibody
(Santa Cruz, CA), or control rabbit IgG was preincubated with nuclear
extracts in ice for 15 min before addition of the labeledDNAprobe. The
mixture was then incubated with the probe for 40 min at 30 C and sub-
jected to non-denaturing gel electrophoresis (5% polyacrylamide, 6%
glycerol, 0.25· Tris–borate–EDTA buﬀer) at 10–12.5 mA at 4 C for
1.5 h. For preparation of the probe and competitors, the following com-
plementary oligonucleotides were used (core consensus sequences for
Smad binding are underlined): PAI-1 SBE, 5 0-AGTATGTCTA-
GACTGA-3 0; PAI-1 mt-SBE (mutant SBE), 5 0-AGTATATGTACAT-
TGA-3 0; Smurf2/203, 5 0-GGCCCAGTCTGGGCCG-30 (located at
209 to 194); Smurf2/130, 5 0-CGCAGGAGACCTCGCC-30
(located at 136 to 121); Smurf2/55, 5 0-GCCCCCGTCTCC-
TCCC-3 0 (located at 61 to 46); Smurf2/+28, 5 0-TCTCTCAGAC-
AAGAGG-3 0 (located at +22 to +37); Smurf2/+80, CTCAGC-
AGACTTCGCA-3 0 (located at +74 to +89).3. Results
3.1. Activation of Smurf2 expression by TGF-b
There are some reports that suggest several factors such as
TGF-b [16,21,22], IL-1a [23] and PDGF (platelet-derived
Table 1
Selective stimulation of Smurf2 promoter (PGV-Bsf-272) activity by
TGF-b
Signal Fold induction P value
Treatment
 +
TGF-b(6.25 pM) 1.000 ± 0.127 2.418 ± 0.149 P < 0.01
TGF-b (400 pM) 1.000 ± 0.127 2.664 ± 0.250 P < 0.001
IL-1a (10 ng/mL) 1.000 ± 0.086 0.842 ± 0.083 N.S.
PDGF (50 ng/mL) 1.000 ± 0.086 1.064 ± 0.052 N.S.
EGF (100 nM) 1.000 ± 0.104 1.297 ± 0.097 N.S.
N.S. not signiﬁcant.
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thermore, we reported that Smurf2 increases in nephritic kid-
neys [17,18]; however, the regulatory mechanisms of Smurf2
expression were not clariﬁed. We investigated whether Smurf2
expression is stimulated by above factors. We found that
Smurf2 mRNA and protein were increased by TGF-b treat-
ment in TGF-b responsive cell line HepG2. mRNA expression
of Smurf2 was evaluated in TGF-b-treated HepG2 cells by
real-time RT-PCR. Smurf2 mRNA signiﬁcantly increased in
a time-dependent manner (Fig. 1A). Additionally, Smurf2 pro-
tein levels also increased in a time-dependent manner (Fig. 1B).
To determine the mechanisms of Smurf2 gene expression, we
constructed reporter plasmids by introducing the promoter re-
gions of the Smurf2 gene into PGV-B vectors as shown in Fig.
2A. PGV-Bsf-1067 and -272 plasmids were transfected into the
TGF-b responsive cell line HepG2. These plasmids showed al-
most the same luciferase activities in TGF-b-treated HepG2
cells (Fig. 2A). Moreover, Smurf2-promoter activities of
PGV-Bsf-272 were stimulated by TGF-b in a dose-dependent
manner (Fig. 2B) as well as those of PGV-Bsf-1067 (data not
shown). Therefore, the reporter assay seems to reﬂect the fea-
ture of Smurf2 expression. Then we tested the eﬀects of several
growth factors and a cytokine on Smurf2 gene expression.
TGF-b signiﬁcantly activated the Smurf2-promoter (Table 1
and Fig. 2A), whereas IL-1a, PDGF and epidermal growth
factor (EGF) did not (Table 1). These data indicate that
TGF-b is a positive regulator of Smurf2 gene expression.Fig. 2. TGF-b-dependent activation of the Smurf2 promoter via TGF-b recep
Smurf2 gene and reporter plasmids. Black squares indicate putative SBEs.
contain GTCT sequences. Their promoter activities were measured by lucifera
was transfected with pCMV-b-Gal into HepG2 cells. After treatment with 4
both luciferase and b-Gal were measured. (B) PGV-Bsf-272 were transfecte
amounts of TGF-b for 24 h, reporter activities were measured. The Smurf2 pr
represent triplicate experiments. Numbers indicate fold activation relativ
means ± S.D.) \P < 0.01 vs column A. \\P < 0.001 vs column A. (C) Inhibitio
Gal were transfected with or without pCMV-Smad7 into HepG2 cells. A
measured. (D) Inhibition of Smurf2 promoter activity by an ALK5 inhibito
After treatment with 6.25 pM TGF-b with or without an ALK5 kinase inhi
represent triplicate experiments.3.2. Eﬀects of Smad7 and TGF-b receptor kinase inhibitor on
Smurf2 expression
Next, to conﬁrm whether stimulation of Smurf2 expression
by TGF-b is mediated via TGF-b receptor signaling pathway,
we evaluate the eﬀects of Smad7, an I-Smad, and a tyrosine ki-
nase inhibitor of TbRI on Smurf2 promoter activity. It is
known that Smad7 blocks TGF-b receptor-mediated phos-
phorylation of R-Smads and/or promotes ubiquitination and
degradation of the receptor complexes [3,25]. As shown in
Fig. 2C, ectopic expression of Smad7 signiﬁcantly inhibited
TGF-b-mediated Smurf2 transcription. One lM SB431542, a
selective inhibitor against ALK (activin receptor-like kinase)5
(TbRI), also signiﬁcantly inhibited TGF-b-mediated Smurf2
transcription (Fig. 2D). In the absence of TGF-b, neithertor. (A) Schematic representation of the upstream region of the mouse
The upper squares contain AGAC sequences and the lower squares
se reporter assay. A reporter plasmid, PGV-Bsf-1067 or PGV-Bsf-272,
00 pM TGF-b for 24 h, cell lysates were prepared and the activities of
d with pCMV-b-Gal into HepG2 cells. After treatment of indicated
omoter was activated by TGF-b in a dose-dependent manner. The data
e to the reporter activity without TGF-b stimulation. (Results are
n of Smurf2 promoter activity by Smad7. PGV-Bsf-272 and pCMV-b-
fter treatment with 25 pM TGF-b for 24 h, reporter activities were
r. PGV-Bsf-272 and pCMV-b-Gal were transfected into HepG2 cells.
bitor (SB431542) for 24 h, reporter activities were measured. All data
2560 N. Ohashi et al. / FEBS Letters 579 (2005) 2557–2563SB431542 nor Smad7 inhibited Smurf2 promoter activities.
These data suggest that TGF-b activates Smurf2 transcription
via the TGF-b receptors.
3.3. Roles of TGF-b-Smad signaling on Smurf2 expression
To determine whether R-Smads mediate Smurf2 induction,
we used an expression plasmid of wild-type Smad3 or a plas-Fig. 3. Eﬀects of DN-Smad3 on the Smurf2 transcription. (A) Activity
of a DN-Smad3. The 3TP-Lux plasmid and pCMV-b-Gal were
transfected with the indicated amounts of pCMV-Smad3-DN (DN)
and/or 0.25 lg of the wild-type Smad3 plasmid (Smad3) into HepG2
cells. After treatment with or without 100 pM TGF-b for 24 h, reporter
activities were measured. \P < 0.05 vs column A. \\P < 0.0001 vs
column D. (B) Eﬀects of DN-Smad3 on the Smurf2 promoter. PGV-
Bsf-272 and pCMV-b-Gal were transfected with pCMV-Smad3-DN
into HepG2 cells. After treatment with or without 6.25 pM TGF-b for
24 h, reporter activities were measured. (C) Eﬀects of DN-Smad3 and
wild-type Smad3 on the Smurf2 promoter. PGV-Bsf-272 and pCMV-
b-Gal were transfected with the indicated amounts of pCMV-Smad3-
DN and/or 0.25 lg of the wild-type Smad3 plasmid into HepG2 cells.
After treatment with or without 6.25 pM TGF-b for 24 h, reporter
activities were measured. All data represent triplicate experiments.mid of DN-Smad3 (Smad3D407E) in the reporter assay. It
was reported that Smad3D407E (DN-Smad3), which is not
phosphorylated by the constitutively active form of TbRI,
inhibits phosphorylation of wild-type Smad2 and Smad3,Fig. 4. SBE-independent activation of Smurf2 promoter. (A) Sche-
matic representation of the mouse Smurf2 reporter plasmids. Black
squares indicate putative SBE (SBE-like) elements. Five SBE-like
elements were disrupted by site-directed mutagenesis to construct
PGV-Bsf-272-mt-5SBE as shown in Section 2. (B) Eﬀect of mutated
SBE-like elements. PGV-Bsf-272 (ﬁlled bars) or PGV-Bsf-272-mt-
5SBE (hatched bars) and pCMV-b-Gal were transfected with or
without the wild-type Smad3 plasmid into HepG2 cells. After
treatment with 100 pM TGF-b for 24 h, reporter activities were
measured. All data represent triplicate experiments. \P < 0.01,
\\P < 0.001, \\\P < 0.0001 vs column A. (C) Smad3 binds to the SBE
in the PAI-1 gene but not to SBE-like elements in the Smurf2
promoter. The known SBE in the PAI-1 gene (PAI-1 SBE) was used as
a 32P-labeled probe in EMSA with nuclear extracts (NE) from HepG2
cells treated with (TGF-b+) or without (TGF-b) 100 pM TGF-b.
Competitors, anti-Smad3 antibody (aSmad3) or control rabbit IgG
were added as indicated. Formation of DNA–protein complex (arrow)
was induced by TGF-b (lane 3) and inhibited in the presence of the
PAI-1 SBE in a dose dependent manner (lanes 4–6) but not by mt-SBE
or SBE-like elements in the Smurf2 promoter (lanes 7–12). The DNA–
protein complex was supershifted by addition of anti-Smad3 antibody
(lane 13, arrowhead).
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To indicate activities of the DN-Smad3, the 3TP-Lux plasmid
containing the SBE site in the PAI-1 promoter was used as a
Smad-dependent reporter plasmid. The results showed that
DN-Smad3 inhibited TGF-b/Smad3-dependent promoter
activity of 3TP-Lux plasmid as shown in Fig. 3A. Therefore,
the DN-Smad3 functioned as a DN form of Smad3 (Fig.
3A). Unexpectedly, DN-Smad3 did not signiﬁcantly aﬀect
Smurf2 expression regardless of stimulation by TGF-b (Figs.
3B and C). In addition, DN-Smad3 had little eﬀects on the
Smurf2 promoter activities even when wild-type Smad3 was
overexpressed, although the overexpression of Smad3 results
in a marginal activation of the promoter (Fig. 3C).
Next we evaluated involvements of Smads binding to puta-
tive SBEs in the upstream region of the Smurf2 gene (Fig.
2A). There are 10 and 5 SBE-like elements in the 1067 to
+103 region and the 272 to +103 region, respectively (Figs.
2A and 4A). Because SBE mutations (AGAC to ACTG or
GTCT to CAGT) signiﬁcantly reduced TGF-b-mediated
SM22 a induction, SBE confers TGF-b responsiveness
[27,28]. To evaluate involvements of the SBE-like elements in
Smurf2 expression, site-directed mutagenesis was performed
to introduce mutations in all ﬁve SBE-like elements in theFig. 5. Contribution of PI3K/Akt pathways to the Smurf2 gene expre
phosphorylation of Akt and Smurf2 expression. Upper panel: HepG2 cells
DMEM. At 30 min before TGF-b treatment, a PI3 kinase inhibitor LY2940
blot analysis with rabbit anti-phosphorylated Akt antibody (Cell Signaling),
272 (ﬁlled bars) or PGV-Bsf-1067 (hatched bars) and pCMV-b-Gal were tran
without 20 lMLY294002 for 24 h, reporter activities were measured. \P < 0.0
PGV-Bsf-1067) activity by LY294002 in HeLa cells. PGV-Bsf-272 (ﬁlled bar
into HeLa cells. After treatment with 400 pM TGF-b with or without 20 lM
column B, \\P < 0.0001 vs column B. (C) Inhibition of PGV-Bsf-272 activ
transfected into HepG2 cells. After treatment with 25 pM TGF-b with or wi
272 was inhibited by LY294002 in a dose-dependent manner. Moreover, PGV
column A, \\P < 0.0001 vs column B. All data represent triplicate experimen272 to +103 region as described in Section 2. A reporter as-
say was performed using the 5· SBE mutant reporter plasmid
(PGV-Bsf-272-mt-5SBE). As shown in Fig. 4B, no remarkable
diﬀerences in Smurf2 promoter activities were noted between
the wild-type and mutant Smurf2 promoters (lane A and B).
This result indicated that the SBE-like elements was not in-
volved in TGF-b-mediated activation of Smurf2 transcription.
On the other hand, overexpression of wild-type Smad3 in-
creased the promoter activity of PGV-Bsf-272 in a SBE-inde-
pendent manner, because it also increased the promoter
activity of PGV-Bsf-272-mt-5SBE (Fig. 4B, lane A vs C, lane
B vs D).
To further evaluate Smad-binding abilities of the ﬁve SBE-
like elements, we performed EMSA assay using a well-known
SBE derived from PAI-I promoter as a probe. As shown in
Fig. 4C, formation of DNA–protein complex was induced by
TGF-b (lane 3) and inhibited in the presence of excess amounts
of unlabeled-PAI-1 SBE in a dose dependent manner (lanes 4–
6) but not by mt-SBE (PAI-I) or SBE-like elements in the
Smurf2 promoter (203, 130, 55, +28 and +80, lanes 7–
12). Considering the results from the EMSA and the reporter
assay, contribution of the ﬁve SBE-like elements on TGF-b-
mediated activation of Smurf2 transcription might be veryssion. (A) Eﬀects of a PI3 kinase inhibitor on TGF-b-mediated
were cultured with 400 pM TGF-b for 0, 15 or 60 min in 0.2% FBS–
02 was added to the cells. These cell lysates were subjected to Western
and rabbit anti-Akt antibody (Cell Signaling). Lower panel: PGV-Bsf-
sfected into HepG2 cells. After treatment with 25 pM TGF-b with or
001 vs column B. (B) Inhibition of Smurf2 promoter (PGV-Bsf-272 and
s) or PGV-Bsf-1067 (hatched bars) and pCMV-b-Gal were transfected
LY294002 for 24 h, reporter activities were measured. \P < 0.001 vs
ity by LY294002 and Akt-KN. PGV-Bsf-272 and pCMV-b-Gal were
thout LY294002 for 24 h, reporter activities were measured. PGV-Bsf-
-Bsf-272 was inhibited by Akt-KN with or without TGF-b. \P < 0.01 vs
ts.
2562 N. Ohashi et al. / FEBS Letters 579 (2005) 2557–2563low. Therefore, TGF-b induces Smurf2 expression via a
SBE-independent mechanism, although we cannot neglect
the possibility that Smad3 activates the Smurf2 promoter in
a SBE-independent manner.
3.4. TGF-b-mediated Smurf2 expression via the PI3K-Akt
pathway
Shin et al. [8] reported that the PI3K-Akt pathway contrib-
utes to TGF-b signal transduction in a Smad-independent
manner. We investigated the eﬀects of PI3 kinase inhibitor
on Smurf2 promoter activity. In HepG2 cells, phosphorylation
of Akt, a downstream kinase of PI3 kinase, was increased by
TGF-b treatment and completely inhibited by LY294002, a
PI3 kinase inhibitor (Fig. 5A, upper panel). In our reporter as-
say using PGV-Bsf-272 and PGV-Bsf-1067, LY294002 eﬀec-
tively inhibited TGF-b-mediated Smurf2 expression (Fig. 5A,
lower panel). Almost the same tendency was shown in the
other cell lines such as HeLa cells (Fig. 5B). In addition,
LY294002 suppressed Smurf2 promoter activity in a dose-
dependent manner (Fig. 5C, column A–D), and Akt-KN sup-
pressed Smurf2 promoter activity with or without TGF-b in
HepG2 cells (Fig. 5C, column A vs E, B vs F). These results
strongly suggest that TGF-b stimulates the Smurf2 promoter
via the PI3K-Akt pathway.4. Discussion
Smurf2, a HECT type ubiquitin ligase, regulates cellular
amounts of TGF-b receptors and various Smads via a ubiqui-
tin–proteasome pathway [11,13,29]. Smurf2 plays important
roles in biological events such as development, tumor forma-
tion, and disease progression [5,12,30]. However, the mecha-
nism involved in the transcriptional control of Smurf2 has
not been elucidated. In the present study, we searched for
the extracellular signaling molecule that regulates Smurf2
expression. Because there are some reports that suggest
TGF-b is upregulated in nephritic tissues [21,31] and since
we found that Smurf2 is increased in nephritic kidneys
[17,18], we paid attention to TGF-b. We demonstrated that
both Smurf2 mRNA and protein are increased by TGF-b stim-
ulation and Smurf2 promoter activity increased in response to
TGF-b. Both an ALK5 inhibitor and Smad7 inhibited TGF-b-
mediated Smurf2 transcription, whereas they did not aﬀect
Smurf2 transcription in the absence of TGF-b stimulation.
Interestingly, Smad3 D407E, a DN form of Smad3, did not
signiﬁcantly aﬀect Smurf2 expression regardless of TGF-b
stimulation. In addition, SBE mutations in the Smurf2 pro-
moter did not aﬀect Smurf2 promoter activity. Furthermore,
formation of DNA–protein complex was induced by TGF-b
and inhibited in the presence of excess amounts of unla-
beled-PAI-1 SBE in a dose-dependent manner but not by
SBE-like elements in the Smurf2 promoter (203, 130,
55, +28 and +80, lanes 7–12, Fig. 4C). These data suggest
that TGF-b activates Smurf2 transcription via TGF-b recep-
tors in a Smad-independent manner. Overexpression of wild-
type Smad3 increased the promoter activity of PGV-Bsf-272.
However, the eﬀect of Smad3 on Smurf2 promoter was
SBE-independent. Smads are critical transducers for TGF-b
signaling, however, Smad-independent pathways also exist
[5]. TGF-b activates PI3K/Akt pathway as well as ERK, p38MAP kinase and JNK [6–8]. In the present study, we found
that Smurf2 promoter activity was suppressed by Akt-KN or
PI3K inhibitor (Fig. 5). PI3K-Akt pathway may be involved
in SBE-independent TGF-b-mediated Smurf2 expression. We
should further investigate the downstream target transcription
factors for PI3K, which regulate Smurf2 transcription in a
Smad-independent manner.
TGF-b signaling is regulated by multiple and complex mech-
anisms [1]. TGF-b signaling is negatively regulated not only by
the I-Smads, Smad6 and 7, but also by ubiquitin-dependent
degradation of Smads and/or TGF-b-receptors by their spe-
ciﬁc ubiquitin ligases, such as Smurfs [14,15] and Arkadia
[32]. In the present study, we found that Smurf2, the ubiquitin
ligase of that controls TGF-signaling to regulate cellular levels
of Smad2 and Smad7, was stimulated by TGF-b itself. Our
ﬁndings that Smurf2 induction is mediated via a Smad-
independent pathway might suggest that precise regulation of
TGF-b-Smad signaling without the inﬂuence of cellular
amounts of Smad2/7, which are down-regulated by Smurf2,
is advantageous.
We previously reported that Smurf2 increased to degrade
Smad2 [17] and Smad7 [18] in some animal models for nephri-
tis. In anti-thymocyte serum nephritis, a rat model of mesan-
gial proliferative glomerulonephritis, we and other
investigators have shown that TGF-b, PDGF and IL-1 are
upregulated in glomerular lesions. In addition, we previously
reported that phosphorylation-dependent activation of Smad3
was involved in the progression of glomerular lesions in this
nephritis [33], and demonstrated decreased levels of Smad2
protein, which were associated with the increases in ubiquiti-
nated Smad2 levels, Smad2 degradation and Smurf2 expres-
sion, in the diseased glomeruli. Furthermore, we recently
reported that the enhanced degradation and ubiquitination
of Smad7 protein in sclerosing mouse kidneys in association
with the increased levels of both TGF-b and Smurf2 induced
unilateral ureteral obstruction [18]. Together with our present
results this suggests that increased Smurf2 and accelerated
Smad2 and/or 7 degradation in these renal lesions could be
promoted by TGF-b but not PDGF or IL-1. In the future,
we will investigate the eﬀects of ALK5, and PI3K inhibitors
on Smurf2 induction and the progression of renal lesions in
these animal models.
Although we cannot exclude the possibility that enhanced
Smurf2 expression by TGF-b is a subordinate event, we pro-
pose the physiological meanings of Smurf2 induction in
nephritis as follows: extracellular matrix (ECM) production
accompanied by progression of nephritis occurred as a result
of Smad3-dependent transcriptional activation of ECM pro-
teins such as ﬁbronectin and collagens. TGF-b activates both
Smad3 and Smad2 via receptor-mediated phosphorylation.
At the same time, Smurf2 was induced via a Smad-indepen-
dent pathway by TGF-b and activated to promote ubiquitin-
dependent degradation of Smad7. Alternatively, the induced
Smurf2 facilitated degradation of Smad2, and as a result, the
activated Smad3 might promote Smad3-dependent transcrip-
tion of ECM proteins. This theory would be supported by
our ﬁndings that Smad3 is activated by TGF-b-signaling dur-
ing the progression of ATS-nephritis [33]. Because Smurf2
induction could activate the TGF-b-Smad3 pathway to pro-
gress ﬁbrosis, inhibition of TGF-b-mediated Smad-indepen-
dent Smurf2 induction might be a future therapeutical
strategy for suppressing ﬁbrosis in the kidneys.
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